FINWIRES · TerminalLIVE
FINWIRES

市場動態:泰國加大紓困措施,因應日益加劇的經濟壓力

-- 根據越南快訊(VN Express)週一報道,泰國正加強應對中東局勢緊張帶來的經濟壓力,並採取一系列生活成本紓困措施。報告引述了泰國經濟部長素帕吉·素圖蓬(Suphajee Suthumpun)的話。 政府正在全國推出3800輛名為「Pum-Puang」的流動售貨車,銷售價格更低廉的商品,尤其是在市場准入有限的偏遠地區。此外,政府也正在擴大「藍旗」(Blue Flag)折扣計畫的覆蓋範圍,在各府和曼谷設立數百個集市,並引入數千個流動攤位。 同時,政府也推出了一項針對農民的補貼貸款計劃,以緩解農民的經濟壓力,利息由借款人和政府共同承擔。 根據該新聞媒體報道,官員表示,這些綜合措施旨在擴大民眾獲得平價商品的管道,並提升家庭購買力。 (市場動態新聞來自與全球市場專業人士的對話。這些資訊據信來自可靠來源,但可能包含傳聞和推測。準確性無法保證。)

Related Articles

Asia

National Australia Bank Shares Down After Resolution of Union Court Proceedings

National Australia Bank (ASX:NAB) shares were down about 1% in recent Monday trade following a Friday settlement with the Finance Sector Union of Australia to resolve court proceedings related to excessive additional working hours for employees.The settlement, reached on a without-admissions basis through mediation, includes the establishment of a health, safety, and well-being framework to mitigate the risks linked to working additional hours, and calls for greater oversight of such risks.The union and the bank said in a joint statement that they are "committed to continuing to work together to ensure fair and sustainable outcomes for all [National Australia Bank] employees."

$ASX:NAB
Asia

Clinuvel Pharmaceuticals Says FDA Removes Post-Authorization Requirement for Implant

Clinuvel Pharmaceuticals (ASX:CUV) said the US Food and Drug Administration (FDA) removed a requirement for a post-authorization phase one study on cardiac repolarization in relation to its Scenesse implant upon reviewing its long-term safety profile, according to a Monday filing with the Australian bourse.Scenesse is used to treat patients with erythropoietic protoporphyria, a disease that causes intolerance to light.The FDA concluded that the study was no longer needed since it would not yield valuable safety information, the filing said.

$ASX:CUV
Asia

XRF Scientific Completes Acquisition of Combustion Gas Analysis Business

XRF Scientific (ASX:XRF) has completed the acquisition of the combustion gas analysis business from Bruker AXS, according to a Monday Australian bourse filing.The company entered a binding agreement to acquire the combustion gas analysis business for $4 million upfront plus a potential $1 million earnout based on 7% of net revenue over three years, an earlier filing showed.

$ASX:XRF